The molecular biology of epithelial ovarian cancer;Biologie moléculaire des cancers épithéliaux de l'ovaire

Bulletin du Cancer

Volumn 99, Issue 12, 2012, Pages 1161-1173

  Leary, Alexandra ^a   Pautier, Patricia ^a   Tazi, Youssef ^a   Morice, Philippe ^a   Duvillard, Pierre ^a   Gouy, Sébastien ^a   Uzan, Catherine ^a   Gauthier, Hél̀ene ^a   Balleyguier, Corinne ^a   Lhommé, Catherine ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Molecular profile; Mutation; Ovarian cancer subtypes; Targeted therapy

Indexed keywords

BEVACIZUMAB;

CANCER PROGNOSIS; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; MOLECULAR BIOLOGY; OVARY CARCINOMA; REVIEW; TUMOR BIOPSY;

EID: 84872330524     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1667     Document Type: Article

References (30)

1. de La Motte Rouge T, Petrella MC, Michels J, et al. New drugs and targeted therapeutic agents in ovarian cancer. Bull Cancer 2009; 96: 1215-24.
2. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm. Hum Pathol 2011; 42: 918-31.
3. Cancer Genoma Research Network, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.
4. Dann RB, DeLoia JA, Timms KM, et al. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2012; 125: 677-82.
5. Carden CP, Yap TA, Kaye SB. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol 2010; 22: 473-80.
6. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005; 11: 6422-30. (Pubitemid 41338978)
7. Matulonis UA, Hirsch M, Palescandolo E, et al. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One 2011; 6: e24433.
8. Sales EPR, Sullivan L, Borger D, et al. A snapshot of personalized care: molecular diagnostics in gynecologic cancer. J Clin Oncol 2012; 30: abstract 5029.
9. Wong KK, Tsang YT, Deavers MT, et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 2010; 177: 1611-7.
10. Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10: 25-38.
11. Jones S,Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-31.
12. Anglesio MS, George J, Kulbe H, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011; 17: 2538-48.
13. Tan DS, Iravani M, McCluggage WG, et al. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 2011; 17: 1521-34.
14. Cho KR, Shih Ie M. Ovarian cancer. Annu Rev Pathol 2009; 4: 287-313.
15. Kelemen LE, Kobel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol 2011; 12: 1071-80.
16. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-91. (Pubitemid 44343542)
17. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 2012; 12: 587-98.
18. Leary A, Gore H. Incorporating bevacizumab into ovarian cancer treatment: practical considerations. ASCO Educational Book 2011: 198-203.
19. Behbakht K, Sill MW, Darcy KM, et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 123: 19-26.
20. Janku F, Wheler JJ,Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30: 777-82.
21. Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010; 120: 2858-66.
22. Buckanovich RJBR, Sella A, Sikic BI, et al. Activity of cabozantinib in advanced ovarian cancer patients: results from a phase II randomized discotinuation trial. J Clin Oncol 2011; 29: abstract 5008.
23. Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin Cancer Res 2005; 11: 5539-48. (Pubitemid 41060831)
24. Makhija S, Amler LC, Glenn D, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010; 28: 1215-23.
25. Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs 2012; June 4 [Epub ahead of print]
26. Chang HL, Pieretti-Vanmarcke R, Nicolaou F, et al. Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines. Gynecol Oncol 2011; 120: 128-34.
27. Carden CP, Stewart A, Thavasu P, et al. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol Cancer Ther 2012; 11: 1609-17.
28. Poveda A, Kaye SB, McCormack R, et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol 2011; 122: 567-72.
29. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012; 4: 136ra68.
30. Penel N, Saleron J, Lansiaux A, et al. Methodological approaches of clinical studies with targeted therapies. Bull Cancer 2008; 95: 185-90. (Pubitemid 351341289)